|Former Common name||No Data|
|H-2 Haplotype||No Data|
|Background strain||No Data|
|Strain development||Developed by Graduate School of Pharmaceutical Sciences, Nagoya City University and Genome Information Research Center, Osaka University in 2006. C57BL/6J background. Main line (RBRC05437, line 3), Subline (RBRC05438, line 9).|
|Strain description||Fad104, factor for adipocyte differentiation 104 (Fndc3b, fibronectin type III domain containing 3B) gene knockout mice. Fad104 is a protein containing 9 repeats of the fibronectin type III domain and a transmembrane domain that transiently expresses at the early stage of adipocyte differentiation. Homozygous mutant mice are die within 1 day after birth. Analyses of MEFs from mutant mice revealed that disruption of this gene caused a reduction in the ability to differentiate, proliferate, adhere, spread and migrate. Heterozygous mutant mice show a less body weight gain than wild-types. Exon 2 was replaced with a neomycin resistant cassette.|
|Colony maintenance||Heterozygote X Wild-type [C57BL/6J(Crlj)]|
|Health Report||No Data|
|Symbol name||fibronectin type III domain containing 3B|
|Common name||No Data|
|Symbol description||No Data|
|Research applications||No Data|
|Specific Term and Conditions||The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Exp. Cell. Res., 315, 809-819 (2009). Exp. Cell. Res., 317, 2110-2123 (2011). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from Dr.Makoto Nishizuka (firstname.lastname@example.org) using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
|Depositor||Imagawa, Masayoshi (Nagoya City University Faculty of Pharmaceutical Sciences)|
|Strain Status /